Results 231 to 240 of about 334,171 (270)

TP53‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, EarlyView.
ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah, Daniel A. Arber, Devendra K. Hiwase   +2 more
wiley   +1 more source

Lymphatic metastasis in non‐small cell lung cancer: recent discoveries and novel therapeutic targets

, 2022
Cancer Communications, Volume 42, Issue 12, Page 1403-1406, December 2022.
Xiayao Diao, Chao Guo, Shanqing Li
wiley   +1 more source

Prophylactic Prednisolone Promotes AAV5 Hepatocyte Transduction Through the Novel Mechanism of AAV5 Coreceptor Platelet-Derived Growth Factor Receptor Alpha Upregulation and Innate Immune Suppression. [PDF]

Hum Gene Ther
Handyside B, Zhang L, Yates B, Xie L, Ismail AM, Murphy R, Baridon B, Su C, Bouwman T, Mangini L, Tahquechi J, Salcido S, Minto WC, Keenan WT, Ntai I, Sihn CR, Bullens S, Bunting S, Fong S.   +18 more
europepmc   +1 more source

Angiotensin II Induces Transactivation of Two Different Populations of the Platelet-derived Growth Factor β Receptor [PDF]

, 2000
Sylvia Heeneman, Judith Haendeler, Yuji Saito, Mari Ishida, Bradford C. Berk   +4 more
openalex   +1 more source

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives

American Journal of Hematology, EarlyView.
ABSTRACT Myelofibrosis (MF) is a myeloproliferative neoplasm that is accompanied by driver JAK2, CALR, or MPL mutations in more than 90% of cases, leading to constitutive activation of the JAK–STAT pathway. MF is a multifaceted disease characterized by trilineage myeloid proliferation with prominent megakaryocyte atypia and bone marrow fibrosis, as ...
Giuseppe G. Loscocco, Paola Guglielmelli
wiley   +1 more source

Reduction in platelet-derived growth factor receptor mRNA in v-src-transformed fibroblasts

, 1995
Qun‐Xing Zhang, Francesca Walker, Antony W. Burgess, Graham S. Baldwin   +3 more
openalex   +1 more source

Local Delivery of Platelet-Derived Growth Factor Receptor–Specific Tyrphostin Inhibits Neointimal Formation in Rats [PDF]

, 2000
Ilia Fishbein, Johannes Waltenberger, Shmuel Banai, Laura Rabinovich, Michael Chorny, Alexander Levitzki, Aviv Gazit, Rita Huber, Ulrike Beate Mayr, S. David Gertz, Gershon Golomb   +10 more
openalex   +1 more source

Topics of Interest in Women With Myeloproliferative Neoplasms

American Journal of Hematology, EarlyView.
Women with MPN: life‐cycle phases, specific risks, and influencing factors. ABSTRACT Overview Sex and gender have emerged as central modifiers of disease biology, phenotype, and clinical outcomes in myeloproliferative neoplasms (MPNs). This review will uniquely highlight issues affecting women with MPN and articulate their relevant determinants ...
Natasha Szuber, Paola Guglielmelli, Naseema Gangat   +2 more
wiley   +1 more source

The TEL/platelet-derived growth factor β receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFβR kinase-dependent signaling pathways

, 1996
Martin Carroll, Michael H. Tomasson, George F. Barker, Todd R. Golub, D. Gary Gilliland   +4 more
openalex   +1 more source

Myc Is an Essential Negative Regulator of Platelet-Derived Growth Factor Beta Receptor Expression [PDF]

, 2000
Sara Oster, Wilson W. Marhin, Charlotte Asker, Linda M. Facchini, Patrick A. Dion, Keiko Funa, Martin Post, John M. Sedivy, Linda Z. Penn   +8 more
openalex   +1 more source